Hikmat Al-Ahmadie

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

Chaitanya Bandlamudi, Daniel Muldoon, Ino de Bruijn, Mingxuan Zhang et autres

Abstract 1292: Multimodal modeling of detailed cancer subtypes and molecular features from >60,000 patients with co-registered H&E images and clinical tumor sequencing.

Kevin Boehm, Madison Darmofal, Arfath Patha, Andrew Aukmerman et autres

Abstract Background: Optimal oncology treatment depends upon detailed cancer subtyping and molecular characterization. However, due to small datasets, prior digital pathology work often grouped detailed histologic subtypes by anatomy. Furthermore, the role of digital pathology as a complement to DNA sequencing rather …

us (code pays fourni par la source)

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

Chaitanya Bandlamudi, Daniel M. Muldoon, Ino de Bruijn, Mingxuan Zhang et autres

The oncogenic impact of somatic driver alterations is shaped by tissue context. Classifying alterations by cancer type and evaluating their context-specific properties requires large cohorts of genomically profiled and clinically annotated tumors. Here, we define cancer type-specific patterns of driver alterations, including …

us (code pays fourni par la source)

Membranous and cytoplasmic Nectin4 expression and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Michal Sternschuss, Karissa Whiting, Cansu Yol, Alyssa Arbuiso et autres

801 Background: Enfortumab vedotin plus pembrolizumab (EV/P) is the standard therapy for metastatic urothelial carcinoma (UC) irrespective of Nectin4 expression. The relevance of membranous (mNectin4) and cytoplasmic (cNectin4) expression remains uncertain. Methods: We retrospectively reviewed an institutional database of patients treated with …

us (code pays fourni par la source)

Mechanistic insights into bacillus Calmette-Guérin (BCG) sensitivity in non-muscle invasive bladder cancer (NMIBC) with ERCC2 alterations.

Vincent J. D'Andrea, Syed Muneeb Alam, Jiaqian Luo, Qiang Li et autres

813 Background: Alterations in the nucleotide excision repair (NER) gene ERCC2 are common in bladder cancer (BC) and confer increased tumor mutational burden (TMB) and neoantigen load. Clinically, ERCC2- altered NMIBC tumors are associated with a favorable response to BCG. Because BCG …

us (code pays fourni par la source)

Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.

Michiel S. Van Der Heijden, Matthew D. Galsky, Ricky S. Joshi, James W.F. Catto et autres

636 Background: In NIAGARA (NCT03732677), addition of perioperative D to neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) demonstrated a significant improvement in event-free survival (EFS) and overall survival and a numerical increase in pathological complete response (pCR) vs NAC and RC alone …

nl, us, es, gb, jp, it, vn, ru, ca (code pays fourni par la source)

HER2 and nectin-4 IHC expression and clinical outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

David H. Aggen, Michal Sternschuss, Karissa Whiting, Aditi Gupta et autres

827 Background: Enfortumab vedotin and pembrolizumab (EV/P) is the standard of care for metastatic urothelial carcinoma (UC). Outcomes in UC based on HER2 IHC expression and correlation between membranous Nectin-4 and HER2 IHC expression have not been reported. Methods: A retrospective cohort …

us (code pays fourni par la source)